Quest Diagnostics Incorporated (DGX)vsNovartis AG ADR (NVS)
DGX
Quest Diagnostics Incorporated
$189.13
-0.90%
HEALTHCARE · Cap: $21.33B
NVS
Novartis AG ADR
$148.34
+1.95%
HEALTHCARE · Cap: $275.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 402% more annual revenue ($56.58B vs $11.28B). NVS leads profitability with a 23.9% profit margin vs 9.1%. DGX appears more attractively valued with a PEG of 1.49. DGX earns a higher WallStSmart Score of 63/100 (C+).
DGX
Buy63
out of 100
Grade: C+
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-26.0%
Fair Value
$166.17
Current Price
$189.13
$22.96 premium
Margin of Safety
-52.0%
Fair Value
$109.95
Current Price
$148.34
$38.39 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Weak financial health signals
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : DGX
The strongest argument for DGX centers on Price/Book. PEG of 1.49 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : DGX
The primary concerns for DGX are Piotroski F-Score.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Key Dynamics to Monitor
DGX profiles as a value stock while NVS is a declining play — different risk/reward profiles.
DGX carries more volatility with a beta of 0.65 — expect wider price swings.
DGX is growing revenue faster at 9.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
DGX scores higher overall (63/100 vs 51/100). Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Quest Diagnostics Incorporated
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Quest Diagnostics is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?